Neil here.

We could have a COVID-19 vaccine in as little as two months, and you could see major returns if you take advantage right away.

On Wednesday, news broke that the Centers for Disease Control and Prevention (CDC) has asked states to prepare for vaccine distribution as soon as late October.

The request, which was made in a letter, asked state governors to remove any barriers that would prevent distribution centers from becoming fully operational by November 1st.

This timeline is impressive, considering we’ve only known about COVID since December and vaccines normally take years to produce.

But this year, the Trump administration has poured $10 billion into an initiative called “Operation Warp Speed,” in an effort to get a viable vaccine ready by Election Day.

So far, around $3 billion has been committed to National Institute of Health… which includes funding for existing vaccine trials. Another $6.5 billion will go toward countermeasure development, which includes scaling up manufacturing and distribution capability.

The administration aims to deliver a whopping 300 million vaccine doses by just January 2021. To put that into perspective, that’s over 91.5% of the 328 million people living in the United States right now.

To me, this points to the value of government funding in research and development efforts.

In the public and private markets alike, this type of funding can be vital to securing more advanced resources and creating more impactful products and services.

Companies that can leverage government funding are often in a better position to fuel faster growth.

And where there’s money pouring in, there’s also the chance for major profit.

There are multiple vaccines in U.S. that have made it to Phase 3 trials.

However, the CDC has not disclosed which vaccine is a front-runner for distribution.

But there are potentially massive returns to be made from whichever company does land on the right vaccine solution and distributes it first.

And folks who can take advantage before distribution begins will have the highest chance of sharing in that success.

That’s why it’s important to look to the experts for the best insights into which vaccine could be a winner.

And there’s no expert more legendary than my friend and colleague Michael Robinson, a Silicon Valley veteran who specializes in all things biotech.

Michael has spent months diligently following the COVID-19 vaccine efforts, and he’s pinpointed one company that he believes could be the biggest gamechanger in the history of medicine.

The company behind this vaccine is still tiny, with only $60 million in sales per year.

But they’re about to begin production of up to one billion doses that could trigger a mind-blowing 58,300% revenue surge by the end of the year.

That’s a once-in-a-lifetime opportunity for folks who take action fast.

It has the potential to transform the $3.2 trillion healthcare sector and do a whole lot more than just prevent COVID, too…. but I’ll let Michael give you the full scoop.

Just click here for all the details.

I’ll be back soon with another update.

Until next time,

Neil Patel